Citation Impact
Citing Papers
Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma
2008
Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer
2008 Science
ATP-Citrate Lyase Links Cellular Metabolism to Histone Acetylation
2009 StandoutScience
Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions
2009 StandoutScience
Metastasis: from dissemination to organ-specific colonization
2009 Standout
Pharmacologic Targeting of Hypoxia-Inducible Factors
2019 StandoutNobel
Cancer–stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis
2012 StandoutNobel
Treatment of kidney cancer
2009 StandoutNobel
Gut microbiota-derived propionate reduces cancer cell proliferation in the liver
2012
Histone deacetylases and cancer
2007
The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer
2008 StandoutNobel
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
2009 StandoutNature
Molecular Understanding and Modern Application of Traditional Medicines: Triumphs and Trials
2007 Standout
Cellular senescence: when bad things happen to good cells
2007 Standout
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
2011 StandoutNature
Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?
2006
Treatment of Obesity with Celastrol
2015 Standout
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
Heat shock proteins as gatekeepers of proteolytic pathways—Implications for age-related macular degeneration (AMD)
2009
Histone Deacetylase Inhibitors and Demethylating Agents: Clinical Development of Histone Deacetylase Inhibitors for Cancer Therapy
2007
Heat shock protein 90: The cancer chaperone
2007
The Epigenomics of Cancer
2007 Standout
Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators
2006
The Natural Compound Cantharidin Induces Cancer Cell Death through Inhibition of Heat Shock Protein 70 (HSP70) and Bcl-2-associated Athanogene Domain 3 (BAG3) Expression by Blocking Heat Shock Factor 1 (HSF1) Binding to Promoters
2013
Epigenetics in Cancer
2008 Standout
Anticancer activities of histone deacetylase inhibitors
2006 Standout
Targeting the phosphoinositide 3-kinase pathway in cancer
2009 Standout
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
2010
Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites
2021 StandoutNobel
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men
2008
Acetylation and deacetylation of non-histone proteins
2005
Drug repurposing: progress, challenges and recommendations
2018 Standout
Molecular chaperones in protein folding and proteostasis
2011 StandoutNature
Causes and consequences of microRNA dysregulation in cancer
2009 Standout
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
Light‐Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy
2015 StandoutNobel
An Acetylation Site in the Middle Domain of Hsp90 Regulates Chaperone Function
2007
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate
2010
Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug
2007
Histone deacetylase inhibitors: molecular mechanisms of action
2007
Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer
2017
The many roles of histone deacetylases in development and physiology: implications for disease and therapy
2008 Standout
Leukaemogenesis: more than mutant genes
2009
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
2014
Hsp70 and CHIP Selectively Mediate Ubiquitination and Degradation of Hypoxia-inducible Factor (HIF)-1α but Not HIF-2α
2009 StandoutNobel
Molecular Genetic Pathways as Therapeutic Targets in Acute Myeloid Leukemia
2008
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
Clonal evolution in cancer
2012 StandoutNature
Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
2009
Epigenetic modifications and human disease
2010 Standout
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
2006 Standout
S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition
2010
Drugging the Cancer Chaperone HSP90
2007
A decade of exploring the cancer epigenome — biological and translational implications
2011 Standout
Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase Pathway
2008 StandoutNobel
HDAC6 Modulates Cell Motility by Altering the Acetylation Level of Cortactin
2007
PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases
2008
Lysine Acetylation: Codified Crosstalk with Other Posttranslational Modifications
2008
Microbiota-Generated Metabolites Promote Metabolic Benefits via Gut-Brain Neural Circuits
2014 Standout
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
2009 StandoutNobel
Regulatory networks defining EMT during cancer initiation and progression
2013 Standout
Histone deacetylase inhibitors in hematological malignancies and solid tumors
2015
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
2012 StandoutNobel
The cancer genome
2009 StandoutNature
Spermidine/Spermine N1-Acetyltransferase-1 Binds to Hypoxia-inducible Factor-1α (HIF-1α) and RACK1 and Promotes Ubiquitination and Degradation of HIF-1α
2007 StandoutNobel
Click Chemistry for Drug Development and Diverse Chemical–Biology Applications
2013 Standout
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
2009 Standout
Explorative Study on Isoform-Selective Histone Deacetylase Inhibitors
2009
New and emerging HDAC inhibitors for cancer treatment
2014
Histone Deacetylase Inhibitors Induce VHL and Ubiquitin-Independent Proteasomal Degradation of Hypoxia-Inducible Factor 1α
2006
Class II Histone Deacetylases Are Associated with VHL-Independent Regulation of Hypoxia-Inducible Factor 1α
2006
Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.
2011
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Transcriptional control of human p53-regulated genes
2008 Standout
Spermidine in health and disease
2018 StandoutScience
Histone Deacetylase Inhibitors: Overview and Perspectives
2007
Rational Combinations Using HDAC Inhibitors
2009
Histone Deacetylase Inhibitors: From Bench to Clinic
2008
Epigenetic regulation in pluripotent stem cells: a key to breaking the epigenetic barrier
2012 StandoutNobel
Histone Deacetylase 6 Regulates Growth Factor-Induced Actin Remodeling and Endocytosis
2007
Causal analysis approaches in Ingenuity Pathway Analysis
2013 Standout
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
Mice Lacking Histone Deacetylase 6 Have Hyperacetylated Tubulin but Are Viable and Develop Normally
2008
Histone deacetylase 10 promotes autophagy-mediated cell survival
2013
Mechanisms of Endocytosis
2009 Standout
Palaeoproteomic evidence identifies archaic hominins associated with the Châtelperronian at the Grotte du Renne
2016 StandoutNobel
Targeting HDACs: A Promising Therapy for Alzheimer's Disease
2011
Works of Michael Pranpat being referenced
Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2
2005
Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90
2005
Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells
2006
Abrogation of Heat Shock Protein 70 Induction as a Strategy to Increase Antileukemia Activity of Heat Shock Protein 90 Inhibitor 17-Allylamino-Demethoxy Geldanamycin
2005
Cotreatment with Vorinostat (Suberoylanilide Hydroxamic Acid) Enhances Activity of Dasatinib (BMS-354825) against Imatinib Mesylate–Sensitive or Imatinib Mesylate–Resistant Chronic Myelogenous Leukemia Cells
2006
Molecular mechanisms of underlying synergistic effect of combinations of histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) with docetaxel and trastuzumab against human breast cancer cells
2005
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl–expressing human leukemia cells
2006